Wajeeh Khan

Tue, Jun 24, 2025, 7:35 AM2 min read

Investors are keenly watching Amrize (AMRZ)  as it completed its spinoff from the Swiss giant Holcim AG (HCMLY) and started trading on the New York Stock Exchange on Monday.

In a post spinoff interview with CNBC, the company’s chief executive, Jan Jenisch, said AMRZ is a “growth company” with “more than 1,000 sites” that currently supply to the entire U.S.

• Meta’s Mark Zuckerberg Says the Technology They’re Developing Will ‘See What You See and Hear What You Hear’

• The Next Trillion-Dollar Boom? 3 Stocks to Buy with 300 Million Humanoid Robots on the Horizon.

• 'Record-Shattering': Warren Buffett’s Berkshire Hathaway Has Now Paid $101 Billion in Cumulative Federal Income Tax

• Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now!

CEO Jan Jenisch expects Amrize to grow at a compound annualized rate of up to 11% moving forward.

According to him, the company will likely attract significant demand from the U.S. investors given it’s America’s largest cement supplier, which has doubled its sales from $6 billion over the past five years.

“I think we have been the most successful company in the last five years in the building sector,” he told CNBC on Monday.

Additionally, AMRZ shares offer industry-leading margins and stand to benefit from the expected increase in construction demand on the back of U.S. commitment to building new AI data centers.

Despite the aforementioned positives, analysts aren’t particularly thrilled about Amrize stock at current levels.

In a research note this morning, Mark Diethelm, senior equity research analyst at Vontobel, warned that a subdued construction market in the U.S. could hurt the cement supplier that completed its spinoff from Holcim this week.   .

Diethelm assumed coverage of AMRZ shares with a “Hold” rating on Monday, saying there isn’t much room to the upside given they’re already trading near his price target.

In fact, the Vontobel expert sees Holcim stock following the Amrize spinoff as better investment for exposure to the construction space since it’s “both a growth and a profitability expansion story.”

Investors should also note that UBS analysts have also initiated coverage of Amrize stock with a “neutral” rating today. Their $53 price target also supports that the company’s shares do not have any meaningful upside potential left.

On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com